A Trial to Evaluate Safety of Firmagon® (Degarelix) in Indian Patients Diagnosed With Advanced Hormone-dependent Prostate Cancer
The purpose of this open-label, single-arm, multicenter, post-marketing trial is to evaluate long-term safety of Firmagon® in approximately 230 Indian patients diagnosed with advanced hormone-dependent prostate cancer requiring androgen deprivation therapy.
Prostate Cancer
DRUG: Degarelix
Frequency of adverse events, Up to Day 364|Severity of adverse events, Up to Day 364|Clinically significant changes in laboratory values (hematology and clinical biochemistry), From baseline to Day 364|Clinically significant changes in vital signs, From baseline to Day 364
Cumulative probability of no Prostate Specific Antigen (PSA) failure, PSA failure defined as an increase in serum PSA of 50%, and at least 5 ng/mL, compared to nadir, measured on two consecutive occasions at least 2 weeks apart, Up to Day 364|Cumulative probability of Progression Free Survival (PFS), PFS defined as PSA failure, death from any cause, or introduction of additional therapy related to prostate cancer, whichever is first, Up to Day 364|Change in International Prostate Symptom Score (IPSS), From baseline to Day 364|Change in physician's satisfaction score, From baseline to Day 364
The purpose of this open-label, single-arm, multicenter, post-marketing trial is to evaluate long-term safety of Firmagon® in approximately 230 Indian patients diagnosed with advanced hormone-dependent prostate cancer requiring androgen deprivation therapy.